Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges.
作者信息
Ren Sijia, Wang Chunguo, Shen Jianfei, Zhu Chengchu
机构信息
Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Zhejiang University School of Medicine, Taizhou 317000, China.
Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Taizhou 317000, China.
出版信息
J Thorac Dis. 2020 Apr;12(4):1615-1620. doi: 10.21037/jtd.2020.03.44.
Abstract
摘要
相似文献
1
Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges.可切除非小细胞肺癌的新辅助免疫治疗：最新进展与未来挑战
J Thorac Dis. 2020 Apr;12(4):1615-1620. doi: 10.21037/jtd.2020.03.44.
2
[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].[可切除非小细胞肺癌新辅助免疫治疗的进展]
Zhongguo Fei Ai Za Zhi. 2024 Feb 20;27(2):138-146. doi: 10.3779/j.issn.1009-3419.2024.102.06.
3
Neoadjuvant immunotherapy for resectable non-small cell lung cancer.可切除非小细胞肺癌的新辅助免疫疗法
Am J Cancer Res. 2021 Jun 15;11(6):2521-2536. eCollection 2021.
4
Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.努力改善可手术切除的非小细胞肺癌的预后：新辅助免疫治疗的前景与挑战。
Curr Oncol Rep. 2020 Aug 15;22(11):109. doi: 10.1007/s11912-020-00969-w.
5
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.非小细胞肺癌的新辅助免疫治疗：现状与未来策略。
J Thorac Oncol. 2020 Aug;15(8):1281-1297. doi: 10.1016/j.jtho.2020.05.020. Epub 2020 Jun 6.
6
Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.可切除非小细胞肺癌新辅助治疗中免疫治疗的现状和未来展望。
Asia Pac J Clin Oncol. 2022 Aug;18(4):335-343. doi: 10.1111/ajco.13665. Epub 2021 Nov 23.
7
Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.基于免疫治疗的新辅助治疗在可切除非小细胞肺癌中的真实世界结局。
Front Immunol. 2023 Sep 25;14:1268251. doi: 10.3389/fimmu.2023.1268251. eCollection 2023.
8
Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.新辅助免疫治疗局部晚期可切除非小细胞肺癌：系统评价和荟萃分析。
Cancer. 2023 Jul 1;129(13):1969-1985. doi: 10.1002/cncr.34755. Epub 2023 Mar 30.
9
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.可切除非小细胞肺癌新辅助免疫治疗的当前方法。
Curr Oncol Rep. 2023 Aug;25(8):913-922. doi: 10.1007/s11912-023-01430-4. Epub 2023 May 30.
10
Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer.非小细胞肺癌新辅助免疫治疗中的临床挑战
Chin J Cancer Res. 2021 Apr 30;33(2):203-215. doi: 10.21147/j.issn.1000-9604.2021.02.08.
引用本文的文献
1
Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study.新辅助治疗和手术后非小细胞肺癌的预后因素：一项回顾性观察研究
J Thorac Dis. 2025 May 30;17(5):2841-2855. doi: 10.21037/jtd-2024-1651. Epub 2025 May 27.
2
Research Trends and Emerging Hotspots of Lung Cancer Surgery during 2012-2021: A 10-Year Bibliometric and Network Analysis.2012 - 2021年肺癌手术的研究趋势与新兴热点：一项十年文献计量学与网络分析
Health Data Sci. 2022 Oct 20;2022:9797842. doi: 10.34133/2022/9797842. eCollection 2022.
3
Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer.新辅助免疫疗法有助于切除具有手术挑战性的肺鳞状细胞癌。
J Thorac Dis. 2021 Dec;13(12):6816-6826. doi: 10.21037/jtd-21-1195.
4
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer.血小板 PD-L1 反映了肿瘤内 PD-L1 的集体表达，并预测了非小细胞肺癌的免疫治疗反应。
Nat Commun. 2021 Dec 1;12(1):7005. doi: 10.1038/s41467-021-27303-7.
5
Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients.在预测肺癌患者新辅助免疫治疗的病理反应方面，吸烟特征优于程序性死亡配体1表达。
Transl Lung Cancer Res. 2021 Sep;10(9):3807-3822. doi: 10.21037/tlcr-21-734.
6
Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review.新辅助免疫疗法联合化疗治疗局部晚期肺鳞状细胞癌：一例病例报告及文献综述
Open Life Sci. 2021 Aug 25;16(1):838-844. doi: 10.1515/biol-2021-0083. eCollection 2021.
7
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.单中心前瞻性研究：纳武利尤单抗联合卡铂及白蛋白紫杉醇新辅助治疗 IIIA-N2 期鳞状非小细胞肺癌 36 例的疗效分析。
Med Sci Monit. 2021 Aug 11;27:e930738. doi: 10.12659/MSM.930738.
8
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.奥希替尼新辅助治疗联合/不联合化疗对比单纯化疗用于可切除 - 突变型非小细胞肺癌：NeoADAURA 研究。
Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19.
9
Neoadjuvant treatment of stage IIIA-N2 in -Mutant/-rearranged non-small cell lung cancer.III A-N2期EGFR突变/ALK重排非小细胞肺癌的新辅助治疗
Transl Lung Cancer Res. 2021 Jan;10(1):607-621. doi: 10.21037/tlcr-20-780.
10
Our experience of lung resection in patients who decline blood transfusion for religious reasons.我们在因宗教原因拒绝输血的患者中进行肺切除手术的经验。
Gen Thorac Cardiovasc Surg. 2021 Jul;69(7):1105-1111. doi: 10.1007/s11748-021-01589-2. Epub 2021 Feb 6.
本文引用的文献
1
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.新辅助抗 PD-1 免疫治疗在复发性胶质母细胞瘤中促进了肿瘤内和全身免疫应答，并带来生存获益。
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.
2
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.新辅助纳武利尤单抗治疗可切除非小细胞肺癌患者肺切除术后的初步结果。
J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276. doi: 10.1016/j.jtcvs.2018.11.124. Epub 2018 Dec 13.
3
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.新辅助与辅助伊匹单抗联合纳武利尤单抗治疗 III 期黑色素瘤的比较。
Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8.
4
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
5
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
6
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
7
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.化疗和靶向治疗在早期非小细胞肺癌中的作用。
Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70. doi: 10.1080/14737140.2018.1409624. Epub 2017 Nov 26.
8
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
9
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
10
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.新辅助免疫疗法比辅助免疫疗法更能有效根除转移性疾病。
Cancer Discov. 2016 Dec;6(12):1382-1399. doi: 10.1158/2159-8290.CD-16-0577. Epub 2016 Sep 23.
Zotero 插件